ATCOR Chief Medical Officer Steven Kesten, MD discusses how to maximize success in decentralized clinical trials. For products targeting cardiovascular disease, incorporation of central aortic blood pressure (BP) measurement and monitoring can improve key decisions during development (go/no go, endpoints, population characteristics, benefit-risk profile, dosing, etc.) and enhance the likelihood of both regulatory and commercial success. The presentation reviews noninvasive central blood pressure measurement and the rationale for use in drug and medical device development programs.